1.Analysis of sequence-tagged site in bcr and abl genes by DNA pooling and dHPLC.
Hong TIAN ; Dao-Ming LIU ; Bing XU ; Wei-Yang ZHENG ; Shu-Yun ZHOU
Journal of Experimental Hematology 2005;13(3):468-471
To investigate the relationship between the single nucleotide polymorphism (SNPs) of the bcr and abl gene and chronic myelogeous leukemia (CML), the 9 sequence-tagged sites (STS) in bcr and abl gene were screened by DNA pooling and denaturing high performance liquid chromatography (dHPLC), and the results were varified by sequencing. The results showed that the polymorphism sites were detected in 4 out of the 9 STS fragments and there were 3 bases different from the reference sequence found in 3 fragments. In conclusion, the novel SNP in U07000 fragment shows significantly different frequencies between CML and controled people.
Chromatography, High Pressure Liquid
;
methods
;
Fusion Proteins, bcr-abl
;
genetics
;
Genes, abl
;
genetics
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
genetics
;
Polymorphism, Single Nucleotide
;
Proto-Oncogene Proteins c-bcr
;
genetics
;
Sequence Analysis, DNA
;
Sequence Tagged Sites
2.Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene.
Ya-zhen QIN ; Yan-rong LIU ; Jin-lan LI ; Hui WANG ; Yan CHANG ; Jia-yu FU ; Guo-rui RUAN ; Hui-lin SHI ; Jing-ying QIU ; Dao-pei LU ; Shan-shan CHEN
Chinese Journal of Hematology 2004;25(7):409-412
OBJECTIVETo investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).
METHODSBy using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR). The RT-PCR products sequencing was performed, the DNA sequences were analyzed in Genebank and the bcr and abl sequences at the fusion site were identified. DNA was amplified by PCR using a set of primers designed according to the sequencing result of RT-PCR products.
RESULTSTwo patients showed typical manifestations of CML-CP. Their RT-PCR products were different from usual M- or micro -type; one was longer than M-bcr/abl but shorter than micro -bcr/abl, the other one was shorter than M-bcr/abl. The RT-PCR products sequencing showed that both products contained bcr and abl gene sequences. The first patient's bcr gene was broken within exon 18, and fused to abl gene exon 2(a2), and a 40 bp of partial abl intron 1b fragment was inserted between them, resulting in a novel in-frame bcr/abl fusion transcript-e18-int-a2 which has not been reported in the literature so far. In the second patient, deletion of abl exon2(a2) led to exon 13(b2) of bcr gene fusing with abl exon 3(a3).
CONCLUSIONUncommon bcr/abl fusion gene may occur in typical Ph(+) CML patient.
Adult ; Fusion Proteins, bcr-abl ; genetics ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; genetics ; Male ; Molecular Sequence Data ; Philadelphia Chromosome ; Reverse Transcriptase Polymerase Chain Reaction ; Sequence Analysis, DNA
3.A multicenter comparison study on the detection of BCR-ABL tyrosine kinase domain point mutation.
Yazhen QIN ; Dongmei WANG ; Chun QIAO ; Hongjie SHEN ; Suxia GENG ; Zeng CAO ; Xiaojun HUANG
Chinese Journal of Hematology 2015;36(11):902-905
OBJECTIVETo investigate the accuracy and consistency of the detection of BCR-ABL tyrosine kinase domain point mutation among different laboratories.
METHODSEvery one of 6 laboratories prepared 10 cDNA samples from tyrosine kinase inhibitors resistant BCR-ABL (P210 or P190) positive patients'bone marrow or peripheral blood. Each cDNA sample was divided into 6 aliquots and delivered to the laboratories. All 6 laboratories tested BCR-ABL point mutations of 60 samples according to their own protocols. Peking University People's Hospital analyzed the comparison results based on both the reports and sequencing chromatogram from all laboratories.
RESULTSAll laboratories reported the same nucleotide and corresponding amino acid mutations in 37 samples (61.7%). Of 60 samples, 53 had confirmed mutation types, and a total of 23 types were included; 1 had no mutation; mutation types of 6 samples could not be determined because of the big differences among chromatograms from different laboratories. Low percentages of mutants were significantly related to results inconsistency (P=0.008). Inconsistent result of one sample was caused by the unique chromatogram of the mutant L248V, and one by the non-coverage amplification of PCR product from different laboratories. Amplification was failed in 3 samples. Testing or sequencing mistakes occurred in 7 samples. The differences in the mutant percentages among laboratories were less than 20% in the 80.6% of samples with confirmed results. Low internal control gene copies (ABL<10 000) were significantly related to both failed amplification and big differences among chromatograms from different laboratories (P=0.005 and <0.001, respectively).
CONCLUSIONProblems in the clinical routine detection of BCR-ABL point mutation could be exposed and improvement could be achieved by sample exchange and comparison. Low percentage of mutant is the main reason which causes the discrepancy of BCR-ABL point mutation results among different laboratories.
Bone Marrow ; DNA Mutational Analysis ; Fusion Proteins, bcr-abl ; genetics ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Point Mutation ; Polymerase Chain Reaction
4.Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia.
Jaehyeon LEE ; Dal Sik KIM ; Hye Soo LEE ; Sam Im CHOI ; Yong Gon CHO
Annals of Laboratory Medicine 2017;37(1):74-76
No abstract available.
Aged, 80 and over
;
Base Sequence
;
Bone Marrow/pathology
;
DNA/chemistry/metabolism
;
Female
;
Fusion Proteins, bcr-abl/*genetics
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*genetics
;
Multiplex Polymerase Chain Reaction
;
Protein Isoforms/genetics
;
Sequence Analysis, DNA
5.Detection of phosphotyrosine in chronic myeloid leukemia cells with PY20 antibody and its clinical applications.
Jing TIAN ; Hai CHENG ; Kai-Lin XU ; Xiu-Ying PAN
Journal of Experimental Hematology 2009;17(4):1056-1060
The objective of this study was to investigate the specificity of detecting the phosphotyrosine level with anti-phosphotyrosine monoclonal antibody PY20 for diagnosis and prognosis of patients with chronic myeloid leukemia (CML) and the possibility of its clinical application. The positive rate of PY20 in 28 newly diagnosed CML patients was detected by flow cytometry using anti-PY20 antibody, the bcr-abl fusion gene was detected by nested RT-PCR, the Ph chromosome was measured by R-banding cytogenetic analysis, and the coincidence of PY20 positive rate with results of bcr-abl fusion gene and Ph chromosome detection was compared. In addition, the positive rate of PY20, the changes of bcr-abl fusion gene and Ph chromosome were determined in follow up 7 CML patients after allo-hematopoietic stem cell transplantation. The results indicated that the positive rates of PY20 in 28 newly diagnosed CML patients in groups of chronic phase (CP), accelerated phase (AP), and blast phase (BP) were (40.31% +/- 1.22)%, (77.28 +/- 1.14)% and (78.12 +/- 1.32)% respectively. The positive rate of PY20 in CP was lower than that in AP and BP (p < 0.05). There was no difference in positive rate of PY20 between AP and BP (p > 0.05). PY20 expression level of leukocytes from peripheral blood and bone marrow showed no difference (p < 0.05). The positive rates of PY20 in patients with CR, PR and NR were (15.56% +/- 1.51)%, (38.73% +/- 2.31)% and (60.43% +/- 2.04)% respectively. The positive and negative coincidence between PY20 and RT-PCR was 92.31% and 95.45% respectively. The positive and negative coincidence between PY20 and Ph Chromosome in newly diagnosed patients was 88.46% and 95.46% respectively. Ph chromosome and PY20 were all negative in 7 CML patients after allo-HSCT. Bcr-abl fusion gene was negative persistently in 5 patients, but in the other 2 patients, the fusion gene was persistently positive. In conclusion, the detection of the level of phosphotyrosine in CML cells has high sensitivity and specificity. The results of PY20 cell positive rate combined with detection of bcr/abl fusion gene and Ph chromosome might be useful in diagnosis as a good index of monitoring.
Adolescent
;
Adult
;
Antibodies, Monoclonal
;
chemistry
;
Female
;
Flow Cytometry
;
Fusion Proteins, bcr-abl
;
genetics
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
genetics
;
metabolism
;
Male
;
Middle Aged
;
Philadelphia Chromosome
;
Phosphotyrosine
;
analysis
;
Reverse Transcriptase Polymerase Chain Reaction
;
methods
;
Sensitivity and Specificity
;
Young Adult
6.Identification bcr-abl fusion gene in leukemia cells with oligonucleotide microarray.
Yan LI ; Jian HUANG ; Jie-Ping CHEN ; Hou-Jie LIANG ; Sheng-Qi WANG
Journal of Experimental Hematology 2004;12(6):743-747
To explore the application value of bcr-abl fusion gene deterction microarray in diagnosis, typing, choosing of treatment variant and prognosis judgment, probe for fusion gene detection was designed, oligonucleotide microarray was prepared; total RNA was extracted, reverse-transcripted and labeled by fluorescence, then cDNA was hybridized with microarray in order to detect bcr-abl fusion gene in leukemia cells. The results showed that better reaction conditions were gained by exploration of hybridizotion temperature and elution conditions, bcr-abl fusion gene in leukemia cells was detected by prepared miccroarray. In conclusion, oligonucleotide microarray is effective in detecting the fusion gene and has some unique advantages and certain clinical application value, but has some deficiency too. If microarray can be improved further, it could be used widely in the field of hematology.
Fusion Proteins, bcr-abl
;
genetics
;
Gene Expression Regulation, Leukemic
;
HL-60 Cells
;
Humans
;
K562 Cells
;
Leukemia
;
genetics
;
pathology
;
Oligonucleotide Array Sequence Analysis
;
methods
;
Reproducibility of Results
7.Correlation between JAK2-V617F mutations and variation of peripheral blood cells among BCR/ABL-negative MPD patients.
Yuan-xin YE ; Xing-bo SONG ; Yi ZHOU ; Bin-wu YING ; Xiao-jun LU
Chinese Journal of Medical Genetics 2012;29(5):582-586
OBJECTIVETo assess the correlation between JAK2-V617F mutation and complete blood counts among patients with BCR/ABL-negative myeloproliferative diseases (MPD).
METHODSOne hundred and ninety one patients were recruited. Retrospectively, their laboratory data were analyzed for the counts of red blood cells (RBC), white blood cells (WBC) and platelets (PLT). And the incidence of JAK2-V617F mutation was determined.
RESULTSThere was significant difference in the incidence of JAK2-V617F mutation between patients with different cell counts (P< 0.01). The incidence of JAK2-V617F mutation has increased with the counts of RBC and PLT, which was the highest (92.86%) among those featuring simultaneous increase in all three series.
CONCLUSIONThe incidence of JAK2-V617F mutation seems to be strongly associated with variation of peripheral blood cell counts among patients with BCR/ABL-negative MPD. Variation of peripheral blood cells, particularly RBC, may be correlated with the rate of JAK2-V617F mutation.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Female ; Fusion Proteins, bcr-abl ; analysis ; Humans ; Janus Kinase 2 ; genetics ; Male ; Middle Aged ; Mutation ; Myeloproliferative Disorders ; blood ; genetics
8.Clinical and cytogenetic analyses of 45 adult patients with acute lymphoblastic leukemia.
Ling CEN ; Min ZHOU ; Tao CHEN ; Rong XIAO ; Jian-he YANG ; Nai-ke JIANG ; Yan ZHANG ; Xu-zhang LU
Chinese Journal of Medical Genetics 2012;29(3):356-359
OBJECTIVETo analyze the correlation between clinical features and cytogenetic finding of 45 adult patients with acute lymphoblastic leukemia (ALL), and to assess the value of chromosomal examination for the diagnosis and prognosis.
METHODSFluorescence in situ hybridization (FISH) was utilized for detecting the BCR/ABL fusion gene and P53 gene. Median survival time (MST) of patients was compared using Log-rank test.
RESULTSRespectively, the MST of patients with white blood cell count (WBC) ≤30 × 10(9)/L, normal karyotype, or without a Philadelphia chromosome were significantly greater than those with WBC > 30 × 10(9)/L, abnormal karyotype or Philadelphia chromosome (P< 0.05).
CONCLUSIONWBC, karyotype abnormalities and presence of Philadelphia chromosome are independent factors for the prognosis of ALL in adult patients.
Abnormal Karyotype ; Adult ; Aged ; Cytogenetic Analysis ; methods ; Female ; Fusion Proteins, bcr-abl ; genetics ; Genes, p53 ; Humans ; Male ; Middle Aged ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; diagnosis ; genetics
9.Relationship between thymus output function in CML patients and their bcr-abl mRNA levels.
Su-Xia GENG ; Xin DU ; Jian-Yu WENG ; Shao-Hua CHEN ; Li-Jian YANG ; Yang-Qiu LI
Journal of Experimental Hematology 2007;15(1):138-141
The study was purposed to analyze the relationship between the content of T-cell receptor excision DNA circles (TREC) and bcr-abl mRNA levels in CML patients and to evaluate the prognostic significance of recent thymic output function detection in patients with chronic myelogenous leukemia (CML). Quantitative detection of TREC and bcr-abl fusion gene transcripts in peripheral blood from 15 CML patients were preformed by real-time PCR. The change of bcr-abl levels in 6 patients was followed-up for two years. The results showed that there was no significant correlation between TREC and bcr-abl mRNA levels in peripheral blood from CML patients for the first attack. Patients who had higher TREC at diagnosis had a larger reduction of bcr-abl after 2 years of follow-up. While out of 2 patients who underwent haemopoietic stem cell transplantation (HSCT), one patient with higher level of TREC before transplantation was confirmed to express undetectable level of TREC by three consecutive detections after transplantation, other one patient was identified to express low level of bcr-abl. It is concluded that high thymic output function in CML patients can be beneficial for killing the residual CML cells.
Adolescent
;
Adult
;
Aged
;
Female
;
Fusion Proteins, bcr-abl
;
biosynthesis
;
genetics
;
Gene Rearrangement
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
immunology
;
Male
;
Middle Aged
;
Proto-Oncogene Proteins c-abl
;
biosynthesis
;
genetics
;
Proto-Oncogene Proteins c-bcr
;
biosynthesis
;
genetics
;
RNA, Messenger
;
biosynthesis
;
genetics
;
Receptors, Antigen, T-Cell
;
analysis
;
immunology
;
T-Lymphocytes
;
chemistry
;
immunology
;
Thymus Gland
;
immunology
10.Activating effects of protein transduction domain mediated BCR/ABL protein on CML T cells.
Qiang LIU ; Ying-min LIANG ; Jin ZHENG ; Xue-yi LI ; Miao-wang HAO ; Li LIU ; Ren-an CHEN
Chinese Journal of Hematology 2003;24(12):644-647
OBJECTIVETo study the activating effect of protein transduction domain (PTD) mediated BCR/ABL protein on T cells from CML patients.
METHODSThe plasmid containing PTD and b3a2 bcr/abl of CML was constructed by genetic engineering and expressed in E. coli. The peripheral blood mononuclear cells from CML patients were stimulated in vitro with purified PTD-BCR/ABL protein and the expression of the early activation antigen CD(69) on CD(8)(+) and CD(4)(+) T cells was detected by flow cytometry (FCM).
RESULTSThe optimal concentration of PTD-BCR/ABL protein for activating CD(8)(+) T cells in vitro was 100 micro g/ml, CD(69) expression peaked in three days stimulation. CD(8)(+) T cells were activated in 10 of 15 CML patients, the expression rate of CD(69) was (15.01 +/- 3.75)%. CD(4)(+) T cells were activated in 4 of 15 patients, the expression rate of CD(69) was (10.32 +/- 3.08)%. Both CD(8)(+) and CD(4)(+) T cells were activated simultaneously in 3 of them. However, neither CD(4)(+) nor CD(8)(+) T cells was activated by stimulation with BCR/ABL protein in all 15 specimens, the expression rate of CD(69) on CD(8)(+) and CD(4)(+) T cells was (1.36 +/- 0.31)% and (1.41 +/- 0.43)%, respectively. There was no difference compared with that of PBS control group (P > 0.05).
CONCLUSIONBy using a PTD-mediated antigen delivering system, exogenous BCR/ABL protein can be delivered into APC, processed and presented onto surface of APC to activate Ag-specific CD(8)(+) and CD(4)(+) T cells in vitro.
Adolescent ; Adult ; Aged ; Amino Acid Sequence ; Antigens, CD ; analysis ; Antigens, Differentiation, T-Lymphocyte ; analysis ; CD4 Antigens ; analysis ; CD8 Antigens ; analysis ; Dose-Response Relationship, Drug ; Female ; Flow Cytometry ; Fusion Proteins, bcr-abl ; genetics ; metabolism ; Gene Products, tat ; genetics ; metabolism ; Humans ; Lectins, C-Type ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; blood ; Male ; Middle Aged ; Recombinant Fusion Proteins ; immunology ; metabolism ; pharmacology ; T-Lymphocytes ; drug effects ; immunology